American Heart Journal
Volume 148, Issue 3 , Pages 399-404 , September 2004

Prognostic value of admission glucose in non-diabetic patients with myocardial infarction

  • Jorik R. Timmer, MD

      Affiliations

    • Department of Cardiology, Isala Klinieken, locatie Weezenlanden, Zwolle, The Netherlands
    • Corresponding Author InformationReprint requests: Dr J. R. Timmer, Department of Cardiology, Isala Klinieken, locatie Weezenlanden, Groot Wezenland 20, 8011 JW Zwolle, The Netherlands.
    • ,
  • Iwan C.C. van der Horst, MD

      Affiliations

    • Department of Internal Medicine, University Hospital Groningen, Groningen, The Netherlands
    • ,
  • Jan Paul Ottervanger, PhD

      Affiliations

    • Department of Cardiology, Isala Klinieken, locatie Weezenlanden, Zwolle, The Netherlands
    • ,
  • Jose P.S. Henriques, PhD

      Affiliations

    • Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Jan C.A. Hoorntje, PhD

      Affiliations

    • Department of Cardiology, Isala Klinieken, locatie Weezenlanden, Zwolle, The Netherlands
    • ,
  • Menko-Jan de Boer, PhD

      Affiliations

    • Department of Cardiology, Isala Klinieken, locatie Weezenlanden, Zwolle, The Netherlands
    • ,
  • Harry Suryapranata, PhD

      Affiliations

    • Department of Cardiology, Isala Klinieken, locatie Weezenlanden, Zwolle, The Netherlands
    • ,
  • Felix Zijlstra, PhD

      Affiliations

    • Department of Cardiology, Thoraxcenter, University Hospital Groningen, Groningen, The Netherlands
    • ,
  • on behalf of the Zwolle Myocardial Infarction Study Group

Received 27 November 2003 ,Accepted 7 April 2004.

References 

  1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction: Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;1:397–402
  2. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction (a review). Drugs. 1992;44:293–325
  3. Zijlstra F, Hoorntje JCA, de Boer MJ, et al.  Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999;341:1413–1419
  4. Mak KH, Moliterno DJ, Granger CB, et al.  Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction (GUSTO-I Investigators: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries). J Am Coll Cardiol. 1997;30:171–179
  5. Waldecker B, Waas W, Haberbosch W, et al.  Type 2 diabetes and acute myocardial infarction (angiographic findings and results of an invasive therapeutic approach in type 2 diabetic versus nondiabetic patients). Diabetes Care. 1999;22:1832–1838
  6. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet. 1996;347:949–950
  7. Fava S, Aquilina O, Azzopardi J, et al.  The prognostic value of blood glucose in diabetic patients with acute myocardial infarction. Diabet Med. 1996;13:80–83
  8. Oswald GA, Smith CC, Betteridge DJ, et al.  Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br Med J (Clin Res Ed). 1986;293:917–922
  9. Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose (independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients). Diabetes Care. 1999;22:1827–1831
  10. Wahab NN, Cowden EA, Pearce NJ, et al.  Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?. J Am Coll Cardiol. 2002;40:1748–1754
  11. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology . Acute myocardial infarction (pre-hospital and in-hospital management). Eur Heart J. 1996;17:43–63
  12. Zijlstra F, de Boer MJ, Hoorntje JCA, et al.  A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328:680–684
  13. Screening for type 2 diabetes. Diabetes Care 2003;26(Suppl 1):S21–4
  14. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26 (Suppl 1):S5–20
  15. Henriques JPS, Ottervanger JP, Zijlstra F. Prognostic importance of left ventricular function after angioplasty or thrombolysis for acute myocardial infarction (long-term results of the Zwolle trial). Cardiovasc Rev Rep. 2001;22:343–348
  16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  17. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187–220
  18. Coutinho M, Gerstein HC, Wang Y, et al.  The relationship between glucose and incident cardiovascular events (a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years). Diabetes Care. 1999;22:233–240
  19. Eschwege E, Richard JL, Thibult N, et al.  Diabetes, hyperglycemia, hyperinsulinemia and risk of cardiovascular mortality (findings of the Paris Prospective Survey, 10 years later). Rev Epidemiol Sante Publique. 1985;33:352–357
  20. Buchanan TA, Xiang AH, Peters RK, et al.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796–2803
  21. Tuomilehto J, Lindstrom J, Eriksson JG, et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350
  22. Malmberg K, Norhammar A, Wedel H, et al.  Glycometabolic state at admission (important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study). Circulation. 1999;99:2626–2632
  23. Mizock BA. Alterations in fuel metabolism in critical illness (hyperglycaemia). Best Pract Res Clin Endocrinol Metab. 2001;15:533–551
  24. DeGeare VS, Boura JA, Grines LL, et al.  Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2001;87:1035–1038
  25. Burns RJ, Gibbons RJ, Yi Q, et al.  The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol. 2002;39:30–36
  26. Gosselink ATM, Liem AL, Reiffers S, et al.  Prognostic value of predischarge radionuclide ventriculography at rest and exercise after acute myocardial infarction treated with thrombolytic therapy or primary coronary angioplasty (the Zwolle Myocardial Infarction Study Group). Clin Cardiol. 1998;21:254–260
  27. Mjos OD. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest. 1971;50:1386–1389
  28. Foo K, Cooper J, Deaner A, et al.  A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart. 2003;89:512–516
  29. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction (an overview of randomized placebo-controlled trials). Circulation. 1997;96:1152–1156
  30. Diaz R, Paolasso EA, Piegas LS, et al.  Metabolic modulation of acute myocardial infarction (the ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group). Circulation. 1998;98:2227–2234
  31. van der Horst ICC, Zijlstra F, van't Hof AWJ, et al.  Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction (the glucose-insulin-potassium study: a randomized trial). J Am Coll Cardiol. 2003;42:784–791
  32. Nunn CM, O'Neill WW, Rothbaum D, et al.  Long-term outcome after primary angioplasty (report from the primary angioplasty in myocardial infarction (PAMI-I) trial). J Am Coll Cardiol. 1999;33:640–646
  33. Grines C, Patel A, Zijlstra F, et al.  Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction (six-month follow up and analysis of individual patient data from randomized trials). Am Heart J. 2003;145:47–57

PII: S0002-8703(04)00194-2

doi: 10.1016/j.ahj.2004.04.007

American Heart Journal
Volume 148, Issue 3 , Pages 399-404 , September 2004

Article Tools

* Image Usage & Resolution